The goal of the Biostatistics and Bioinformatics Core (Core B) is to address the statistical design and analysis needs of the Yale SPORE in Lung Cancer (YSILC) Projects, the other Cores, the Developmental Research Program (DRP), and the Career Development Program (CDP). To accomplish this goal we have assembled a highly interactive team of cancer biostatisticians and bioinformaticians who will work collaboratively with basic, clinical, translational, and population science researchers to advance the frontiers of cancer medicine.
The specific aims of the Biostatistics and Bioinformatics Core are:
Aim 1 : Provide collaboration and consulting in the design and analysis of basic, translational, population and clinical studies for YSILC;
Aim 2 : Oversee data management and ensure that data collected on all YSILC studies are of high quality and evaluated with statistical rigor;
and Aim 3 : Design and monitor the statistical conduct of clinical trials, ensuring data are collected and evaluated with statistical rigor and innovation.
For Aim1 the Core will address the analytic and informatics questions arising from the SPORE projects. Services provided by the Core will range from planning activities to consulting on specific analytic questions. More specifically, the Core will schedule regular meetings with the YSILC investigators, and maintain an open door policy for any biostatistical and bioinformatics questions.
For Aim 2 the Core will work closely with the investigators to analyze clinical trial data, next generation sequencing data, and bioinformatics data mining.
For Aim 3 the Core will design and monitor the statistical aspects of clinical trials for safety, efficacy and futility. Since the observed data can have characteristics different from what was hypothesized, the Core will conduct regular interim analyses, dynamically update the power calculations, develop new statistical and bioinformatics methodology as needed, provide timely suggestions to YSILC investigators, and thus play an important role in the projects in the YSILC. Biostatistics and Bioinformatics is also a key partner in the YSILC with representation on their Senior Leadership Team and participation in all core meetings.

Public Health Relevance

Well-designed, executed, and analyzed studies are critical to advancing the treatment and care of patients with lung cancer. Biostatistics and bioinformatics both have a critical role in the design, analysis, and interpretation of data from these studies that help to inform treatment and prevention strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-04
Application #
9529579
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Lopez Sambrooks, Cecilia; Baro, Marta; Quijano, Amanda et al. (2018) Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res 78:5094-5106
Wilson, Frederick H; Politi, Katerina (2018) ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discov 8:676-678
Wang, Guangchuan; Chow, Ryan D; Ye, Lupeng et al. (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Anastasiadou, Eleni; Jacob, Leni S; Slack, Frank J (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18:5-18
Bisserier, Malik; Wajapeyee, Narendra (2018) Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood 131:2125-2137
Chow, Ryan D; Chen, Sidi (2018) Cancer CRISPR Screens In Vivo. Trends Cancer 4:349-358

Showing the most recent 10 out of 74 publications